Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
Sponsor: Eli Lilly and Company
Summary
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo. The study will last approximately 35 weeks.
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-C
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
342
Start Date
2026-04
Completion Date
2027-09
Last Updated
2026-04-22
Healthy Volunteers
No
Conditions
Interventions
LY3537031
Administered SC.
Placebo
Administered SC.
Locations (1)
Gastroenterology Health Partners Loc. 1
Louisville, Kentucky, United States